

85-year-old male presenting with
worsening fatigue, dyspnea on
exertion, and weight gain

Mohaned Serdah, MS3


Edward Gillis, DO

Brad Kincaid, MD


Cardiac MR- Axial Scout




Cardiac MR- Coronal Scout




T1- Axial TSE




Short Axis




4 Chamber View




T1 Scout- Pre-Gadolinium



T1 Scout- Post Gadolinium



Short Axis Late Gadolinium Enhancement







?

Cardiac Amyloidosis

4-Chamber View




T1 Scout- Post Gadolinium



Diffuse, patchy enhancement consistent with infiltrative disease such as amyloidosis.

Short Axis Late Gadolinium Enhancement



Diffuse sub-endocardial enhancement, consistent with infiltrative disease such as amyloidosis

Cardiac Amyloidosis

- Cardiac amyloidosis is protein deposition and aggregation of amyloid within the myocardium.
 - Involvement can be sub-endocardial or transmural depending on the type of amyloid disease.
- There are two types of amyloid disease which make up 95% of cardiac amyloidosis:
 - Light Chain Amyloidosis (AL)
 - Transthyretin Amyloidosis (ATTR)

Cardiac Amyloidosis

- Amyloid cardiomyopathy typically manifests as symptoms of heart failure, which include:
 - Dyspnea, fatigue, edema, angina, pre-syncope.
- Severe cardiac amyloidosis does lead to HFpEF because the thickened ventricular myocardium results in impaired diastolic function/filling.
- Additional cardiac manifestations include small vessel disease, conduction system disease, and pericardial disease.

Cardiac Amyloidosis

- Echocardiogram shows LV wall thickness and EKG shows low voltage amplitudes.
- Cardiac MRI is also useful in diagnosis.
 - Typical findings include late gadolinium enhancement with diffuse, patchy involvement.
 - Cardiac MRI is highly sensitive (93%) and specific (70%).
- Endo-myocardial biopsy is nearly 100% sensitive, and is used for definitive diagnosis.

Cardiac Amyloidosis

- Management of the disease depends on the type of amyloidosis the patient has.
 - AL can be treated with alkylating agents, proteasome inhibitors, immuno-modulators, and anti-CD 38 monoclonal antibody.
 - ATTR can be treated with TTR blockers, silencers, and fibril disrupters.
- Regardless of the type of amyloid disease, patients with HFpEF are treated symptomatically.
 - Treatment includes salt restriction and diuresis.

References

1. Austin, Bethany, et al. "Delayed Hyper-Enhancement Magnetic Resonance Imaging Provides Incremental Diagnostic and Prognostic Utility in Suspected Cardiac Amyloidosis." *NeuroImage, Journal of American College of Cardiology*, 15 Dec. 2009, www.sciencedirect.com/science/article/pii/S1936878X09006627?via%3Dihub.
2. Donnelly, Joseph P., et al. *Cardiac Amyloidosis: An Update on Diagnosis and Treatment*. Cleveland Clinic Journal of Medicine, 19 Feb. 2019, www.mdedge.com/ccjm/article/153514/cardiac-amyloidosis-update-diagnosis-and-treatment.
3. Dubrey, et al. "Clinical Features of Immunoglobulin Light-Chain (AL) Amyloidosis with Heart Involvement." *OUP Academic*, Oxford University Press, 1 Feb. 1998, academic.oup.com/qjmed/article/91/2/141/1582352.
4. Serdah, M., Kincaid, B., Gillis E. Cardiac Amyloidosis. Radiology Online 2020. University of Connecticut Health.